Detail akcie Sinovac Bio online

Business Summary: Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Sinovac Biotech Ltd revenues decreased 70% to $448.3M. Net loss applicable to common stockholders totaled $105.9M vs. income of $107.9M. Revenues reflect Mainland China segment decrease of 66% to $381.1M, Foreign countries segment decrease of 82% to $67.2M. Net loss reflects Interest income decrease of 55% to $85.1M (income), Rental Expense increase from $3.5M to $7.7M (expense).